COMETRIQ

COMETRIQ® is indicated for the treatment of patients with progressive, metastatic medullary thyroid cancer (MTC).  For more information about COMETRIQ®, visit www.COMETRIQ.com.

WARNING: PERFORATIONS AND FISTULAS, and HEMORRHAGE

  • Perforations and Fistulas: Gastrointestinal perforations occurred in 3% and fistula formulation in 1% of COMETRIQ®-treated patients.  Discontinue COMETRIQ® in patients with perforation or fistula.
  • Hemorrhage: Severe, sometimes fatal, hemorrhage including hemoptysis and gastrointestinal hemorrhage occurred in 3% of COMETRIQ®-treated patients.  Monitor patients for signs and symptoms of bleeding.  Do not administer COMETRIQ® to patients with severe hemorrhage.

Please see additional Important Safety Information for COMETRIQ® (cabozantinib), including Boxed Warnings, at www.COMETRIQ.com.